WeVote
Log In

Bill

Bill

A 4275

Prohibits SHBP, SEHBP, and Medicaid from denying coverage for maintenance medications for chronic conditions for covered persons solely because of change in health benefits plan or pharmacy benefits manager.

2024-2025 Regular Session Introduced by Verlina Reynolds-Jackson and 1 co-sponsor

Prohibits NJ health plans and Medicaid from denying chronic disease maintenance medications solely due to plan or pharmacy manager changes, ensuring medication continuity during coverage transitions.

Reported and Referred to Assembly Appropriations Committee
#healthinsur #medicaid #pharmaceutic
0
WeVote Research Nonpartisan
Bill Summary · A 4275

Legislative bill overview

Bill A 4275 prohibits New Jersey's State Health Benefits Plan (SHBP), State Employee Health Benefits Plan (SEHBP), and Medicaid from denying coverage for maintenance medications treating chronic conditions when a covered person switches health plans or pharmacy benefits managers. The bill ensures continuity of medication access during transitions between insurance plans.

Why is this important

Patients with chronic conditions (diabetes, hypertension, heart disease, etc.) depend on consistent medication regimens. Forced interruptions when switching plans can cause health deterioration, emergency room visits, or hospitalizations. This bill protects vulnerable populations—including state employees, retirees, and low-income Medicaid beneficiaries—from coverage gaps that force them to choose between affording medications and other necessities.

Potential points of contention

  • Cost implications: Health plans and pharmacy managers may argue this restricts their ability to negotiate drug costs or manage formularies, potentially increasing premiums for all covered persons
  • Definition ambiguity: "Maintenance medications" and "chronic conditions" lack precise statutory definitions in the bill summary, creating implementation uncertainty about which drugs are protected
  • Market competition concerns: Requirements to cover medications regardless of formulary changes could limit plan flexibility to compete on cost or encourage use of preferred, more affordable alternatives

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.